Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Summary not available.
Summary not available.
Ra Medical Systems has completed a stock-for-stock merger with Catheter Precision, aimed at enhancing its cardiac electrophysiology market presence. David Jenkins, CEO of Catheter Precision, will serve as Executive Chairman. The transaction includes a conversion of $25 million in debt to non-voting Convertible Preferred Stock, granting Catheter Precision stakeholders approximately 87.7% of RMED’s equity. Ra Medical anticipates raising up to $9.3 million in equity financing, reinforcing its financial position with an estimated $12.5 million in net cash for two years of operating capital.
Medtronic plc (NYSE:MDT) will participate in the 41st annual J.P. Morgan healthcare conference on January 9, 2023. CEO Geoff Martha is scheduled to present at 9:00 a.m. PST (11:00 a.m. CST). Following the presentation, key executives including CFO Karen Parkhill will engage in a Q&A session. A live webcast of the event will be available on the company’s investor relations site, with an archive accessible later that day. Medtronic continues to lead in healthcare technology, addressing over 70 health conditions globally.
Medtronic has announced the enrollment of the first patient in the Expand URO clinical trial, a study evaluating the safety and performance of the Hugo™ robotic-assisted surgery (RAS) system for urologic procedures. Conducted at Duke University Hospital, this multi-center trial aims to enroll up to 122 patients across six U.S. sites. The Hugo RAS system is intended for various urologic surgical procedures, promising benefits like fewer complications and quicker recovery times. This trial is conducted under an Investigational Device Exemption from the FDA.
Summary not available.
Medtronic plc (NYSE:MDT) announced an 8% increase in its fiscal year 2023 third quarter cash dividend, now at $0.68 per ordinary share. This dividend, payable on January 13, 2023, to shareholders of record by December 21, 2022, maintains the company's commitment to returning value to shareholders. Medtronic has a long history as a member of the S&P 500 Dividend Aristocrats index, having increased its annual dividend for 45 consecutive years. The announcement aligns with the company's earlier plans communicated in May 2022.
Medtronic (NYSE:MDT) announced the completion of enrollment in the SPHERE Per-AF Trial, evaluating the Sphere-9 cardiac ablation catheter with the Affera mapping system for persistent atrial fibrillation. This pivotal trial, pivotal for FDA approval, included 477 patients across 23 centers in the U.S. and Europe. The Sphere-9 catheter uniquely offers both radiofrequency and pulsed field ablation in one device. Results will be assessed over 12 months. The trial follows Medtronic's acquisition of Affera in August 2022, enhancing its cardiac solutions portfolio.
Medtronic plc (NYSE:MDT) will participate in the Evercore ISI 5th annual HealthCONx conference on November 29, 2022. Geoff Martha, CEO, and Karen Parkhill, CFO, will address questions starting at 5:10 p.m. EST. A live webcast will be accessible via the Investor Events link at Medtronic's Investor Relations, with an archived session available later. Medtronic is a leader in healthcare technology, committed to addressing complex health issues globally.
Medtronic reported its fiscal Q2 2023 results with revenues of $7.6 billion, a 3% decline and a 2% organic growth. GAAP EPS stood at $0.32, down 67%, while non-GAAP EPS was $1.30, down 2%. Key drivers included TAVR, Pacing, and International Diabetes, despite challenges from slower market procedure volumes and cost inflation. Guidance was updated to forecast a revenue growth of 3.5%-4% in the second half of the fiscal year, with expected non-GAAP EPS between $5.25 to $5.30.